 Mass High Tech | Zalicus (ZLCS) To Discontinue Further Synavive Development In Rheumatoid ... iStockAnalyst The company said it achieved primary endpoint compared to placebo but missed key secondary endpoint compared to prednisolone. The Phase 2b trial demonstrated that patients treated with Synavive achieved a statistically significant improvement in signs ... Zalicus slumps after ending Synavive development "Better Than Nothing" Doesn't Cut It for Zalicus Zalicus Has Sufficient Funds Until 2014 |
